ATF6B is a transcription factor that acts in the unfolded protein response (UPR) pathway by activating UPR target genes during endoplasmic reticulum (ER) stress 1. It binds DNA at the 5'-CCAC[GA]-3' half of the ER stress response element (ERSE) when NF-Y is bound to the full ERSE sequence 1. In the central nervous system, ATF6β specifically regulates calreticulin expression, an ER molecular chaperone with high calcium-binding capacity that promotes neuronal survival under ER stress and excitotoxicity 2. ATF6β deficiency decreases calreticulin expression and increases anxiety-like behavior and hyperactivity through elevated corticotropin-releasing hormone signaling in emotional brain regions 3. Disease relevance includes identification as a prognostic marker in colon cancer, where ATF6B is implicated in ER stress-related pathways affecting tumor survival and immune responses 4. ATF6B also appears involved in autoimmune disease pathogenesis, with knockdown affecting B cell maturation and immunoglobulin production in systemic lupus erythematosus models 5. Clinically, CRISPR-Cas9-mediated C-terminal deletion of ATF6B enhances membrane protein production in engineered cells by modulating UPR pathway capacity 6, suggesting therapeutic potential for biotechnology applications.